Underlying all that I do is the fundamental belief that all kids of any age and any level of ability deserve the opportunity to laugh, play, and cause some trouble


Caregiver Profile

Caregiver Profile

Meet Dr. David Fogelman


Medical School

  • Mount Sinai School of Medicine , 2009 , New York , NY


  • Columbia University, St. Luke’s-Roosevelt Hospital Center , 2010 , New York , NY


  • Spaulding Rehabilitation Hospital , 2013 , Boston , MA


  • Rehabilitation Institute of Chicago , 2015 , Chicago , IL

Philosophy of Care

Most people, no matter how many physicians they need to see, spend an overwhelming majority of their time working, playing, and living their lives outside of the doctor’s office. As a practitioner of Physical Medicine and Rehabilitation, I am responsible for helping my patients define their relationships with their lives outside of the time they spend in my direct care.

It is an honor, a privilege, and above all a great adventure to work with children and adolescents with special needs. Underlying all that I do is the fundamental belief that all kids of any age and any level of ability deserve the opportunity to laugh, play, and cause some trouble. I know I can help with that.


David Fogelman, MD began his professional career in engineering school and learned a lot about how to look at the world in terms of cause and effect. He worked in R&D for a Fortune 500 technology company for a few years after college before leaving the field for medical school. Having an engineer’s mind and a doctor’s training really helps him efficiently find what he can do best for his patients and colleagues.


  • American Board of Physical Medicine and Rehabilitation
  • American Board of Physical Medicine and Rehabilitation, Pediatric Rehabilitation Medicine


Publications powered by Harvard Catalyst Profiles

  1. Exercise to enhance neurocognitive function after traumatic brain injury. PM R. 2012 Nov; 4(11):908-13. View abstract
  2. Exercise, sports participation, and musculoskeletal disorders of pregnancy and postpartum. Semin Neurol. 2011 Sep; 31(4):413-22. View abstract
  3. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011 Apr; 31(4):1417-20. View abstract
  4. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368. View abstract
  5. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30. View abstract
  6. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42. View abstract
  7. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51. View abstract
  8. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45. View abstract
  9. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42. View abstract
  10. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008 Jan; 61(1):167-75. View abstract
  11. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol. 2007 Mar; 59(4):429-37. View abstract
  12. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am. 2004 Oct; 13(4):711-35, x. View abstract